Critical to an understanding of the pulmonary disease in cystic fibrosis (CF) and the development of effective gene therapies is a definition of the distribution and regulation of CF gene expression in adult human lung. Previous studies have detected the product of the CF gene, the CF transmembrane conductance regulator (CFTR), in submucosal glands of human bronchi. In this report, we have characterized the distribution of CFTR RNA and protein in the distal airway and alveoli of human lungs. Samples from eight human lungs were analyzed for CFTR expression by in situ hybridization and immunocytochemistry. CFTR was detected in a subpopulation of epithelial cells at every level of the distal lung, including proximal, terminal, and respiratory bronchioles, and the alveoli. However, there was substantial variation in the level of CFTR expression between samples. In bronchioles, CFIR protein localized to the apical plasma membrane and was found primarily in a subpopulation of nonciliated cells. CFIR was expressed in the same distribution as the Clara cell marker CC10 in proximal bronchioles, however, expression was discordant in the more distal bronchioles and alveoli where-CC10 was not detected. These studies suggest that epithelial cells of the distal lung may play a primary role in the pathogenesis of CF as well as expand the spectrum of target cells that should be considered in the development of gene therapies. (J. Clin. Invest. 1994. 93:737-749.) 
Introduction
Cystic fibrosis (CF)' is the number one genetic cause of death in the Caucasian population ( I ). Although multiple organs are affected in this disease, the most morbid and life threatening pathology occurs in the lung. Poor mucociliary clearance with excessive mucous production causes obstructive lung disease and chronic bacterial infections leading to bronchiectasis and respiratory failure. Isolation of the gene responsible for CF has provided insight into the molecular basis of this disease (2) . The product of this gene, called the CF transmembrane conductance regulator (CFTR), is a chloride channel that is primarily localized to the apical surface of epithelial cells. Mecha- 1 . Abbreviations used in this paper: CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; COPD, chronic obstructive pulmonary disease. Critical to an understanding of the basic molecular pathology of CF pulmonary disease is a definition of the normal distribution and regulation of CFTR expression in lung. Studies of CFTR expression in proximal airway structures such as human bronchus and nasal tissue have shown low levels ofCFTR mRNA and protein in cells ofthe surface epithelium (3) (4) (5) . In contrast, high levels of CFTR were demonstrated in epithelial cells of human submucosal glands that are normally restricted to the very proximal airway that is supported with cartilage (6) . While these studies provide insight into pathophysiology ofCF in the proximal airway, their relationship to disease in the bronchioles and alveoli is unclear. A previous report using in situ hybridization of human fetal lungs suggests that CFTR mRNA levels are extremely high prenatally and decline dramatically after birth (7) .
The distal lung can be divided into the conducting airways, which are comprised of an extensive network of bronchioles, and alveoli, where gas exchange with the blood occurs (8) . Four general structures can be identified based on morphological criteria: (a) proximal bronchioles, which have a pseudostratified epithelium but in contrast to bronchi do not contain cartilage; (b) terminal bronchioles, which have a simple columnar to cuboidal epithelium; (c) respiratory bronchioles, which have a discontinuous simple cuboidal epithelium interrupted by alveoli and alveolar ducts; and (d) alveoli, the gas-exchanging region of the lungs (8) We report the localization of CFTR mRNA and protein in distal airways and alveolar regions of human lung. In an attempt to identify the cell types that express CFTR in the distal airway, we have compared the pattern of mRNA expression with the Clara cell marker CC10. These studies have implications to the pathophysiology of CF lung disease as well as the design of rational gene therapies.
Methods
Lung samples. Tissue specimens were obtained from the lungs ofeight patients under a variety of circumstances. Table I summarizes salient features of the donors from which the tissues were derived. Two samples were obtained at the time of surgical lobectomy for lung cancer;
Cystic Fibrosis Gene Expression in Human Lung nontumorous resected regions were selected for analysis, however, each patient had evidence of chronic obstructive pulmonary disease (COPD). These tissues were placed on ice immediately after resection and frozen in OCT within 30 min. The remaining samples were obtained in the setting of lung transplantation. Two samples (Normal I and Normal2) were obtained from portions of donor lungs that were not used for transplantation. These specimens were perfused with Uro Collins solution and stored for 0.5-4 h on ice. The Normal 1 sample was excised from a resected lung after perfusion in the transplant recipient. Both were frozen in OCT within 30 min of resection. The remaining four samples, COPD1, COPD2, IB, and PAP, were derived from the diseased lungs ofthe transplant recipients who were diagnosed with COPD, idiopathic bronchiectasis, and pulmonary alveolar proteinosis, respectively. These samples were also frozen in OCT within 30 min of resection. All samples were stored at 1 34IC until they were sectioned. In situ analysis ofCFTR and CCJO mRNA. Frozen sections (6 Mum) were fixed in PBS containing 4% paraformaldehyde for 3-4 h followed by dehydration through a graded series ofethanol. In situ hybridization was performed as described previously (6) . Briefly, dehydrated fixed sections were treated in 10 ug/ml proteinase-K at 30C for 30 min followed by acetylation in acetic anhydride and dehydration through a graded series of ethanol. Sections were hybridized to UTP and CTP "S-labeled sense and antisense RNA probes generated from the CFTR R-domain ( 1,899-2,623 bp [9] ) and CCl0 ( 1-361 bp [10] ) cDNAs at a concentration of I07 cpm/ml for 16-18 h at 540C. After washing and RNAse treatment, sections were coated in NTB-2 photoemulsion and developed at indicated times. An additional control for nonspecific hybridization included pretreatment of sections with 200 gg/ml RNAse A before hybridization with antisense probes.
Immunofluorescent detection of CFTR and Na+/K+-A TPase.
CFTR protein was localized as previously described using a polyclonal antibody generated against a COOH-terminal peptide of CFTR (residues 1468-1480) designated a-1468 (6) . Na+/K+-ATPase was localized using a mouse monoclonal antibody to the purified alpha subunit of Na+/K+-ATPase ( I1 ). Briefly, frozen sections (6 tim) were fixed in -20°C methanol for 10 min followed by air drying. Sections were blocked with PBS containing 20% donkey serum (DS) and protease inhibitors (2.5 ,g/ml of soybean trypsin inhibitor and 1 qg/ml each of leupeptin, chymostatin, pepstatin, and aprotinin) for 30 min at room temperature. Sections were then incubated sequentially in 5 /g/ml a-1468 CFTR antibody and protease inhibitors for 90 min followed by incubation in undiluted hybridoma supernatantagainst Na+/ K+-ATPase for 60 min. After washing in 1.5% DS/PBS, sections were incubated in 5 ,g/ml of both donkey anti-rabbit FITC-conjugated antibody and donkey anti-mouse Texas red-conjugated antibody for 30 min.
Peptide competition experiments were performed by preincubating 0.5 mg/ml peptide (residues 1468-1480 of CFTR protein) with 0.25 mg/ml of a-1468 in PBS containing 1.5% DS and protease inhibitors overnight at 4°C before immunofluorescent staining. Control uncompeted antibody was incubated under the same conditions but without peptide. Bronchioles were analyzed for peptide-competed signal in serial sections. Additional sections were incubated with and without secondary antibody to control for nonspecific secondary antibody binding and autofluorescence, respectively.
Quantification of CFTR mRNA expression. Morphometry of CFTR in situ data involved analysis of at least four sections from each ofthe human lung samples analyzed. Identification ofairway epithelial structures were based on the following criteria: proximal bronchiole, noncartilaginous airway with a pseudostratified epithelium; terminal bronchiole, airway with a simple columnar/ cuboidal epithelium that is not interrupted by alveolar ducts; respiratory bronchiole, small diameter airway with a simple cuboidal epithelium that is interrupted by alveolar ducts; and alveoli-composed of cuboidal type II and squamous type I cells. At least six random fields of each structure (proximal bronchiole, terminal bronchiole, respiratory bronchiole, and alveoli) were analyzed for the frequency of cells expressing CFTR mRNA > 10-fold above background levels of CFTR mRNA. Sections were analyzed for total number of CFTR mRNA-expressing cells per total number of nuclei in each structure and total number of CFTR mRNA expressing cells per square micron of total cellular area in each structure. CFTR mRNA-expressing cells were selected as those cells that expressed > 10-fold abundance of grains as compared with acellular regions in the same field. Cellular volumes and total numbers ofcells were calculated from outlined epithelial regions of proximal bronchioles, terminal bronchioles, respiratory bronchioles, and alveoli. Four of the eight samples analyzed were quantitated. Because of the high levels of mRNA expressed in a subset of cells, darkfield photomicrographs tended to be misleading in quantification due to bleeding of the saturated signal. Hence, only bright field photomicrographs were used for quantification. Results are presented as the average ± 1 SD. Statistical comparison was performed by the Student's t test.
Due to the limiting quantities of CFTR antibody, only one section from each sample was analyzed. This gave insufficient numbers of sections and independent bronchioles to analyze for quantification. The same criteria as used with in situ hybridization were used for the identification of proximal and terminal bronchioles. Extensive autofluorescence in the most distal regions ofthe lung made it impossible to accurately address CFTR expression in the respiratory bronchioles and alveolar regions.
Results
CFTR mRNA localization. The cellular distribution of CFTR mRNA in lung was analyzed by in situ hybridization using an RNA probe to the R domain of human CFTR. Fig. 1 contains representative examples from two patients of in situ hybridization to proximal bronchioles (A-C), terminal bronchioles (D-G), respiratory bronchioles (H-J), and alveolar regions (K-M). Each sample demonstrated hybridization to the antisense probe that was not present when the sample was pretreated with RNAse (data not shown) or when it was hybridized to a sense probe (Fig. 1, A, D , H, and K). In general, hybridization was restricted to a subset ofepithelial cells found in both airway and alveoli. Table II (Fig. 1 B) to signal that was barely above background in 4±3% of epithelial in sample Normal2 (Fig. 1  C) . This heterogeneity may reflect the clinical status of the No conclusions as to the cell type expressing CFTR in the bronchioles could be made, as cilia were not retained after tissue preparation for in situ analysis. However, in situ grains were clustered in cells of the alveolar region that appeared cuboidal in shape, a finding most consistent with expression in type II pneumocytes rather than the squamous type I pneumocytes or intraalveolar macrophages (which were interpreted as lying within the lumen of the airspace).
CFTR protein localization. Tissue sections were analyzed for expression of CFTR protein using a polyclonal antibody directed against a COOH-terminal peptide ofCFTR. The specificity and sensitivity of this antibody for immunolocalizing CFTR in tissues has been described previously (6) . The specificity of CFTR immunoreactive staining in bronchioles was determined in single immunofluorescent experiments using serial sections stained with CFTR antibody preincubated with peptide antigen. Fig. 2 , A and B, shows CFTR-immunoreactive staining in a proximal and terminal bronchiole that was absent when the antibody was preincubated with peptide antigen (Fig. 2 C) . Fluorescence signal was also absent when the primary antibody was omitted (data not shown). Tissue sections were also incubated with antibodies to CFTR and another membrane marker, the Na+/K+-ATPase, that localizes to the basal lateral surface of epithelial cells. Fig. 3 contains examples of CFTR expression in a proximal bronchiole (A) and terminal bronchiole (B). CFTR antibody bound to a subpopulation ofairway epithelial cells in bronchioles offive ofthe six samples analyzed; the signal consistently localized to the apical surface of these cells. CFTR expression was primarily observed in nonciliated cells, as visualized under Nomarski optics (see arrows, Figs. 2 B and 3 A) CCJO mRNA localization. In an attempt to further characterize the cell type that expresses CFTR, three tissues samples that showed high-level CFTR hybridization were also analyzed for expression of the cell-specific marker CC10 by in situ hybridization. This gene encodes a 10-kD secreted protein that is believed to be specific to a subtype ofClara cells ( 10, 12) . Very high levels of hybridization to the antisense CC10 probe were demonstrated in > 50% of the cells ofthe proximal bronchioles (Fig. 4 B) of all three patients analyzed. Serial sections hybridized with the sense probe (Fig. 4 A) Fig. 4 B) and was absent from these regions in the two other samples (Normal2 and COPD3; data not shown). Signal was absent in the alveolar regions from all samples analyzed.
To more closely analyze the potential overlap of CC IO and CFTR mRNA expression, serial sections from the three samples described above were hybridized to either the CC10 or CFTR antisense mRNA probes. I. _--.. Previous studies have focused primarily on the expression of CFTR in surface epithelial cells of proximal airway structures such as the nose, trachea, and bronchus. Functional evidence for the existence of the CFTR chloride channel has been demonstrated in surface epithelial cells of the proximal airway ( 13 ), however, attempts to detect and localize the CFTR protein and RNA have been difficult (3) (4) (5) . One hypothesis is that CFTR plays a role in the normal physiology ofthese cells but it is expressed at very low levels (6) . We recently characterized the expression of CFTR in human bronchus using techniques of in situ hybridization and immunocytochemistry (6) . Consistent with previous studies, we found low levels of CFTR in the surface epithelium. However, substantial expression of CFTR expression was found in serous cells and ducts of the submucosal glands. This directly implicates an important mucous-producing structure ofthe proximal lung in the pathogenesis of CF lung disease. It distribution of CFTR expression in distal airways and alveolar regions of adult human lung. This study demonstrates detect-able levels of CFTR RNA and protein in a subpopulation ofepithelial cells in every structure distal to the bronchus, including proximal, terminal, and respiratory bronchioles, and alveoli. Although the pattern of expression within the lung was fairly consistent between patients, in that 1-10% highly expressing cells could be found throughout all levels of the distal lung, the intensity of signal varied substantially from patient to patient. This sample-specific variation in CFTR expression remains unexplained, but could be related to environmental influences and/or heterogeneity of expression within subsegments of an individual lung.
The general pattern of CFTR expression in the distal lung. that emerged from our studies has implications in several areas of CF biology. Morphometric analysis of CFTR-expressing cells normalized to cellular area in the various airway structures shows a statistically significant trend that revealed highest levels in respiratory bronchioles as compared with proximal bronchioles (twofold, P < 0.001) and alveoli (fivefold, P < 0.001 ). Comparison ofterminal and respiratory bronchioles showed no statistical differences in the abundance of CFTR mRNA-expressing cells, suggesting that these structures may be functionally related in their capacity to facilitate CFTR-mediated chloride transport. An additional recurrent finding was that CFTR did not appear to be expressed uniformly throughout the lung, in that a minority of highly expressing cells ( 1- 10% of total cells) can be seen in bronchioles and alveoli. This is reminiscent ofthe pattern ofCFTR expression in the submucosal gland ducts of human bronchus where 1-2% of the duct cells expressed high levels (> 50 fold over background) of CFTR mRNA and protein (6) . This pattern of expression is consistent with regulation of chloride transport through a minority subpopulation of cells in a heterogeneous epithelium. Models of this type of chloride transport regulation have been extensively studies in systems such as the amphibian skin where mitochondria rich flask cells, which constitute 1-2% of the entire dermal layer, are the sole route of chloride uptake (14, 15) .
In the bronchioles it is clear that ciliated cells do not express detectable levels ofCFFR protein, suggesting that other cells in these epithelia may be involved in CFTR expression. The distribution and biology of nonciliated cells of human distal airway are not well described. Extrapolation from studies in nonhuman primates ( 16) suggests that the distal airways contain a variety ofcell types, including ciliated cells, mucous cells, basal cells, and nonciliated secretory cells containing electron-dense granules (also known as Clara cells [ 17 ] imal bronchioles demonstrated extensive expression of the Clara cell marker CC 10 within regions that also express CFTR (see Fig. 6 for summary). The resolution of this analysis was insufficient to study colocalization at a cellular level. However, the lack ofcomplete concordance between CFTR and CC 10 in 
